Structural Heart Disease: Definition, Clinical Context, and Cardiology Overview

Structural Heart Disease Introduction (What it is)

Structural Heart Disease is an umbrella term for abnormalities in the heart’s physical structures.
It is a category of cardiovascular conditions, not a single diagnosis.
It commonly involves the valves, chambers, septa, or great vessels.
It is frequently encountered in general cardiology, echocardiography, heart failure care, and “structural heart” procedural programs.

Why Structural Heart Disease matters in cardiology (Clinical relevance)

Structural Heart Disease matters because anatomy drives physiology in the cardiovascular system. When a valve is narrowed, a chamber is enlarged, or a septal defect is present, blood flow patterns change in predictable ways—often leading to symptoms, complications, or both. For learners, Structural Heart Disease is a core framework that links physical findings (like murmurs) to hemodynamics (pressure and flow) and to clinical decisions (medical therapy vs repair or replacement).

From a patient-care perspective, Structural Heart Disease can influence:

Symptoms and functional status: shortness of breath, reduced exercise tolerance, chest discomfort, or syncope can reflect obstructed outflow, volume overload, or impaired filling.
Risk stratification: the presence and severity of structural abnormalities often helps clinicians estimate risks such as heart failure progression, arrhythmias, stroke, or sudden cardiac death (risk estimates vary by clinician and case).
Diagnostic clarity: many cardiac complaints are non-specific; identifying (or excluding) structural disease with imaging narrows the differential diagnosis.
Treatment planning: modern cardiology includes medical therapy, catheter-based interventions, and surgery; structural anatomy frequently determines which pathway is appropriate.
Longitudinal follow-up: structural lesions can be stable for years or evolve over time, so periodic reassessment is often part of care.

The term is also used in other cardiology subfields. In electrophysiology (EP), for example, “structural heart disease” may describe an underlying substrate (scar, dilation, hypertrophy) that influences arrhythmia mechanisms and the safety or effectiveness of certain therapies.

Classification / types / variants

Structural Heart Disease is best classified by what structure is abnormal and whether the condition is congenital or acquired. Common practical groupings include:

Valvular heart disease
Stenosis (restricted opening): commonly aortic stenosis, mitral stenosis.
Regurgitation (leakage): commonly mitral regurgitation, aortic regurgitation, tricuspid regurgitation.
Mixed lesions (both stenosis and regurgitation can coexist).
Cardiomyopathies (heart muscle and chamber disorders)
Dilated cardiomyopathy: enlarged ventricle with reduced contractility.
Hypertrophic cardiomyopathy: increased wall thickness, sometimes with outflow obstruction.
Restrictive cardiomyopathy: impaired filling due to stiffness.
Arrhythmogenic cardiomyopathy: structural changes that may promote ventricular arrhythmias.
Note: Some cardiomyopathies are genetic, some inflammatory, toxic, metabolic, or idiopathic.
Congenital heart disease (present at birth, sometimes diagnosed in adulthood)
Septal defects: atrial septal defect (ASD), ventricular septal defect (VSD).
Outflow tract lesions: pulmonary stenosis, tetralogy of Fallot (repaired or unrepaired).
Patent ductus arteriosus (PDA) and other great vessel connections.
Aortopathies and great vessel disease
Aortic root/ascending aorta dilation, aneurysm, or dissection risk syndromes.
Coarctation of the aorta (often congenital).
Pericardial and structural constraints
Constrictive pericarditis or significant pericardial thickening/calcification can functionally “restrict” filling and may be considered in structural differentials.
Prosthetic and device-related structural issues
Mechanical or bioprosthetic valve degeneration or dysfunction.
Prior repairs (rings, clips, occluders) that require surveillance.

Another helpful axis is hemodynamic consequence:

Pressure overload (e.g., aortic stenosis)
Volume overload (e.g., regurgitant valves, shunts)
Impaired relaxation/filling (e.g., restrictive physiology)
Obstructed flow (e.g., hypertrophic obstructive physiology, congenital obstructions)

Relevant anatomy & physiology

Understanding Structural Heart Disease starts with the heart as a pump with four chambers, four valves, and two circulations.

Left heart (high pressure)
Left ventricle (LV) ejects blood through the aortic valve into the systemic circulation.
Left atrium (LA) receives pulmonary venous blood and transmits it through the mitral valve into the LV.
Structural problems here often cause pulmonary congestion and reduced systemic perfusion when severe.
Right heart (lower pressure)
Right ventricle (RV) ejects through the pulmonic valve into the pulmonary arteries.
Right atrium (RA) receives systemic venous blood and transmits it through the tricuspid valve into the RV.
Right-sided structural disease often relates to volume overload, pulmonary hypertension physiology, or systemic congestion.
Valves as one-way flow regulators
Valves open and close based on pressure gradients. Stenosis increases resistance to forward flow, while regurgitation creates backward flow and increases volume work.
Septa and shunts
The interatrial and interventricular septa separate oxygenated from deoxygenated blood. Defects can create left-to-right or right-to-left shunting depending on pressures, changing pulmonary blood flow and oxygenation.
Coronary circulation and myocardial performance
While coronary artery disease is not always labeled “structural” in everyday usage, myocardial ischemia and infarction can create structural consequences (scar, remodeling, papillary muscle dysfunction) that drive cardiomyopathy or valvular regurgitation.
Conduction system interactions
Structural changes (hypertrophy, dilation, fibrosis, scar) can alter conduction and support arrhythmias such as atrial fibrillation (AF) or ventricular tachycardia (VT). This is a key bridge between structure and rhythm.

Physiology concepts that recur in Structural Heart Disease include preload, afterload, contractility, compliance, and ventricular-arterial coupling. Many symptoms arise when compensatory mechanisms (increased heart rate, chamber dilation, neurohormonal activation) become insufficient or maladaptive over time.

Pathophysiology or mechanism

The unifying mechanism in Structural Heart Disease is an anatomic abnormality that changes cardiac hemodynamics, which then drives remodeling and clinical consequences.

Common mechanistic patterns include:

Stenotic lesions (outflow obstruction)
A narrowed valve or outflow tract increases resistance to forward flow.
The upstream chamber generates higher pressures (e.g., LV pressure overload in aortic stenosis).
Over time, pressure overload may lead to hypertrophy and impaired relaxation, and symptoms can emerge when the heart cannot augment output with exertion.
Regurgitant lesions (volume overload)
Backward flow increases the volume handled by a chamber (e.g., LV volume overload in aortic or mitral regurgitation).
Chambers may dilate to accommodate extra volume, initially preserving output.
Chronic dilation can increase wall stress and eventually reduce systolic function in some patients.
Shunts (abnormal connections)
A defect allows blood to move along a pressure gradient.
Left-to-right shunts can increase pulmonary blood flow and enlarge right-sided chambers.
Long-standing shunting may contribute to pulmonary vascular remodeling; the trajectory varies by lesion size, location, and patient factors.
Cardiomyopathies and remodeling
Primary myocardial diseases or secondary remodeling (from pressure/volume overload, ischemia, toxins, inflammation) change chamber size, shape, and function.
Fibrosis and disarray can contribute to diastolic dysfunction and arrhythmia propensity.
Mechanisms and natural history vary substantially by etiology and genotype (varies by clinician and case).
Aortic and great vessel structural disease
Abnormal connective tissue, hypertension-related degeneration, or congenital patterns can promote dilation.
Wall stress and geometry influence risks and follow-up strategies (varies by protocol and patient factors).

A key teaching point is the distinction between primary structural pathology (e.g., degenerative calcific aortic stenosis) and secondary functional consequences (e.g., “functional” mitral regurgitation due to LV dilation that pulls the valve apparatus apart). In practice, both can coexist.

Clinical presentation or indications

Structural Heart Disease often presents through symptoms, exam findings, incidental imaging findings, or complications. Typical clinical scenarios include:

Exertional dyspnea (shortness of breath) or reduced exercise tolerance
Chest pressure or discomfort with exertion (not specific to coronary disease)
Syncope or near-syncope, particularly with exertion in obstructive lesions
Palpitations or known arrhythmia (e.g., AF) with evidence of chamber enlargement
Heart failure signs: peripheral edema, orthopnea, elevated jugular venous pressure
A new or changing heart murmur on physical examination
Stroke or systemic embolic event prompting evaluation for cardiac sources (context-dependent)
Incidental finding of valve disease, chamber dilation, or congenital defect on echocardiography
Prior congenital or valvular surgery with new symptoms or surveillance imaging needs
Pulmonary hypertension workup revealing right-sided dilation or shunt physiology

In procedural contexts, “structural heart” may also refer to catheter-based therapies (for example, transcatheter valve interventions or septal defect closure) considered when anatomy and clinical factors align.

Diagnostic evaluation & interpretation

Evaluation typically combines history, physical examination, and cardiac testing, with imaging at the center.

Clinical assessment

History
Symptom pattern (exertional vs resting), progression, triggers, and associated features (syncope, angina-like symptoms, edema).
Congenital history, rheumatic fever history (where relevant), family history of cardiomyopathy or sudden death, and prior interventions.
Physical examination
Murmurs (timing, location, radiation), extra heart sounds, and signs of volume overload.
Evidence of pulmonary congestion or systemic venous congestion.
Exam findings suggestive of specific lesions can guide testing, but imaging is usually needed for confirmation.

ECG and laboratory tests

Electrocardiogram (ECG) may show chamber enlargement patterns, conduction delays, ischemic changes, or arrhythmias.
Labs are supportive rather than diagnostic for most structural lesions.
Natriuretic peptides may reflect wall stress in heart failure syndromes.
Troponin may be relevant in acute presentations but is not specific for structural diagnoses.
Additional testing depends on suspected etiology (varies by protocol and patient factors).

Imaging: the cornerstone

Transthoracic echocardiography (TTE)
First-line tool for many patients. Clinicians assess:
Valve anatomy, motion, and hemodynamic effect (stenosis vs regurgitation patterns)
Chamber size and function (systolic and diastolic)
Estimates of pulmonary pressures and right heart function
Shunts and congenital anatomy (sometimes limited by acoustic windows)
Transesophageal echocardiography (TEE)
Provides higher-resolution views of valves and atria. Common uses include:
Detailed valve mechanism assessment
Endocarditis complication assessment (in the right clinical context)
Guidance for certain transcatheter procedures (center- and case-dependent)
Cardiac computed tomography (CT)
High-detail anatomy of valves (including calcification), annular dimensions, and the aorta.
Often used in transcatheter valve planning and aortic disease assessment.
Cardiac magnetic resonance (CMR)
High-quality quantification of ventricular volumes and function.
Tissue characterization (fibrosis/scar) that may inform cardiomyopathy evaluation.
Helpful for complex congenital anatomy in selected patients.
Cardiac catheterization
Measures intracardiac pressures and assesses coronary anatomy when indicated.
Can clarify discordant noninvasive findings or evaluate pulmonary hypertension physiology in selected cases.

Interpretation is generally integrative: clinicians combine anatomy (what looks abnormal) with physiology (what the lesion does to flow and pressures) and symptoms (clinical impact). Severity grading and timing considerations vary by guideline, clinician, and patient factors.

Management overview (General approach)

Management of Structural Heart Disease is individualized and commonly multidisciplinary. A useful framework is to match therapy to (1) the lesion, (2) its physiologic consequence, and (3) the patient’s goals and comorbidities.

Conservative and monitoring strategies

Some structural findings are mild, incidental, or stable over time.
Periodic reassessment with clinical review and repeat imaging may be used to track progression (intervals vary by protocol and patient factors).
Lifestyle and risk-factor management (e.g., blood pressure control) may be part of broader cardiovascular care, but recommendations are individualized.

Medical therapy (supportive and disease-modifying where applicable)

Medication choices typically target the consequences of structural disease, such as:

Heart failure physiology (congestion, reduced output, neurohormonal activation)
Rate/rhythm control when arrhythmias coexist
Antithrombotic therapy in contexts like atrial fibrillation or prosthetic valves (indication depends on lesion and patient factors)
Afterload reduction strategies in some regurgitant lesions or cardiomyopathies (approach varies by clinician and case)

Not all structural problems have a medication that corrects the anatomy. For many lesions, drugs help symptoms and hemodynamics while clinicians monitor for progression or consider intervention.

Interventional (catheter-based) therapies

Modern “structural heart” cardiology includes transcatheter options that may be considered based on anatomy, risk profile, and local expertise, such as:

Transcatheter aortic valve replacement (TAVR) for selected aortic stenosis cases
Transcatheter edge-to-edge repair for selected mitral or tricuspid regurgitation cases
Balloon valvotomy in select stenotic valve disease scenarios
Closure devices for selected ASDs, PDAs, or other defects
Left atrial appendage occlusion in selected patients (often discussed in the context of AF and bleeding risk rather than purely structural anatomy)

Appropriateness depends on imaging-defined anatomy and patient-level risks (varies by clinician and case).

Surgical therapies

Surgery may be used when anatomy is not suitable for catheter-based repair, when long-term durability is a priority, or when multiple issues need correction simultaneously. Examples include:

Surgical valve repair or replacement
Aortic root/ascending aorta repair in selected aortopathies
Congenital defect repair and re-operations in adult congenital heart disease

Many programs use a multidisciplinary heart team (often including cardiologists, interventional cardiologists, cardiothoracic surgeons, imaging specialists, anesthesia, and nursing) to align anatomy, physiology, and patient goals.

Complications, risks, or limitations

Complications and limitations depend on the specific lesion and its severity, but common themes include:

Heart failure (reduced or preserved ejection fraction syndromes), congestion, and reduced exercise capacity
Arrhythmias
Atrial fibrillation associated with atrial enlargement and elevated filling pressures
Ventricular arrhythmias associated with scar, cardiomyopathy, or hypertrophy
Thromboembolism and stroke risk
Often context-dependent (e.g., AF, prosthetic valves, severe chamber dilation)
Pulmonary hypertension due to left-sided filling pressures, shunt physiology, or pulmonary vascular remodeling
Infective endocarditis risk in certain valve conditions and prosthetic material contexts (risk varies by patient factors)
Progressive remodeling
Chamber dilation, hypertrophy, or decline in systolic function over time
Sudden cardiac death risk in selected cardiomyopathies (risk assessment varies by clinician and case)
Procedure-related risks (when interventions are pursued)
Bleeding, vascular complications, stroke, valve dysfunction, conduction disturbances requiring pacing, kidney injury from contrast, and peri-procedural complications (risk varies by procedure and patient factors)
Imaging limitations
Echo windows may be suboptimal, requiring TEE, CT, or CMR.
Some measures can be discordant across modalities, requiring integrative interpretation.

Prognosis & follow-up considerations

Prognosis in Structural Heart Disease is highly variable and depends on:

Type of lesion (valve disease vs cardiomyopathy vs congenital vs aortic disease)
Severity and hemodynamic impact
Degree of obstruction or regurgitation
Presence of elevated filling pressures or pulmonary hypertension
Ventricular function and remodeling
LV and RV size and systolic/diastolic performance
Symptoms and functional capacity
Symptomatic status often signals physiologic significance, though symptom perception varies.
Comorbidities
Hypertension, chronic kidney disease, lung disease, diabetes, and coronary disease can influence course and treatment options.
Timing and durability of intervention
Outcomes may differ between repair vs replacement, surgical vs transcatheter approaches, and early vs late referral (varies by clinician and case).
Adherence to follow-up and surveillance
Many conditions require periodic imaging to detect progression or device degeneration.

Follow-up commonly focuses on symptom review, physical exam, rhythm monitoring when relevant, and repeat imaging to reassess anatomy and function. Post-procedure follow-up may also include surveillance for prosthetic function, paravalvular leak, thrombosis, or endocarditis signs (monitoring strategies vary by protocol and patient factors).

Structural Heart Disease Common questions (FAQ)

Q: What does Structural Heart Disease mean in plain language?
It refers to a problem with the heart’s “hardware,” such as the valves, walls, chambers, septum, or the nearby aorta. It is a broad category rather than a single diagnosis. The term is often used to organize evaluation and treatment around anatomy and blood-flow effects.

Q: Is Structural Heart Disease the same as heart failure?
Not necessarily. Structural abnormalities can cause heart failure, and heart failure can also lead to structural remodeling, but the terms are not interchangeable. Heart failure describes a clinical syndrome, while Structural Heart Disease describes an anatomic substrate.

Q: How is Structural Heart Disease usually detected?
Echocardiography is commonly the first major test because it shows valve function, chamber size, and pumping performance. Additional tests like cardiac CT or cardiac MRI may be used for more detailed anatomy or tissue characterization. The evaluation is typically guided by symptoms, exam findings, and clinical context.

Q: Does Structural Heart Disease always require surgery or a procedure?
No. Some findings are mild or stable and are managed with monitoring and medical therapy aimed at symptoms or associated conditions. When anatomy is severe or complications develop, catheter-based or surgical interventions may be considered, depending on patient factors and imaging findings.

Q: What is a “structural heart team” or “structural heart clinic”?
It usually refers to a multidisciplinary group that evaluates patients with valve disease, congenital lesions, or other anatomic cardiac problems. The team often combines imaging expertise, interventional options, and surgical perspectives. The goal is to match the patient’s anatomy and physiology to an appropriate treatment pathway.

Q: Are transcatheter procedures the same as open-heart surgery?
They are different approaches. Transcatheter procedures are performed through blood vessels (or other access routes) using catheters and imaging guidance, while surgery typically involves direct operative repair or replacement. Which approach is considered depends on anatomy, risks, and local expertise (varies by clinician and case).

Q: If I have a murmur, does that mean I have Structural Heart Disease?
A murmur can be a clue, but it is not a diagnosis by itself. Some murmurs are “innocent,” while others reflect valve disease or abnormal flow patterns. Imaging—most often echocardiography—is used to determine whether a structural abnormality is present.

Q: Can Structural Heart Disease cause arrhythmias like atrial fibrillation?
Yes, structural changes such as atrial enlargement, ventricular hypertrophy, or scar can increase the likelihood of arrhythmias. Arrhythmias can also worsen symptoms by reducing filling time or coordinated contraction. Evaluation often considers both rhythm and structure together.

Q: What should someone expect for follow-up and monitoring?
Follow-up commonly involves periodic clinical visits and repeat imaging to track severity, chamber size, and function. The frequency depends on the lesion type, severity, symptoms, and whether a repair or prosthetic device is present (varies by protocol and patient factors). Monitoring may also include ECGs or rhythm assessment when indicated.

Q: Is Structural Heart Disease inherited or congenital?
Some forms are congenital (present at birth) and may be diagnosed later in life. Some cardiomyopathies and aortopathies have genetic contributions, while many valve problems are acquired with age or related to other conditions. Whether genetics are relevant depends on the suspected diagnosis and family history (varies by clinician and case).

drrehan